Brief: United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
24/03/2025 12:04
March 24 (Reuters) - United Laboratories International Holdings Ltd 3933.HK: THE UNITED LABORATORIES AND NOVO NORDISK ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR UBT251, A GLP-1/GIP/GLUCAGON TRIPLE RECEPTOR AGONIST Source text: ID:nEQ6XYm3ka Further company coverage: 3933.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Laboratories International Holdings
See all newsBrief: United Laboratories International Receives Milestone Payment From Novo
Brief: United Laboratories International Says NMPA Accepts Insulin Degludec And Liraglutide Injection Marketing Registration Application
Brief: United Laboratories International Posts HY Profit Attributable RMB 347.6 Million
China's United Laboratories half-year profit drops 82%
Brief: United Laboratories International Expects HY Net Profit RMB 340 Million